There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biolinerx (BLRX), Voyager Therapeutics Inc (VYGR) and AC Immune SA (ACIU) with bullish sentiments.
Biolinerx (BLRX)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biolinerx, with a price target of $4. The company’s shares closed yesterday at $0.71, close to its 52-week low of $0.67.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -15.3% and a 29.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Biolinerx is a Strong Buy with an average price target of $3, representing a 321.2% upside. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $2 price target.
.
See today’s analyst top recommended stocks >>
Voyager Therapeutics Inc (VYGR)
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Voyager Therapeutics Inc, with a price target of $25. The company’s shares closed yesterday at $12.32, close to its 52-week low of $11.
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -5.0% and a 37.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Voyager Therapeutics Inc with a $22.50 average price target, implying an 82.7% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.
.
AC Immune SA (ACIU)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on AC Immune SA today and set a price target of $18. The company’s shares closed yesterday at $8.89.
Fein observed:
“Our 12-month price target of $18/share is based on an equally weighted composite of (a) $19/share, as a 35x multiple of taxed and diluted FY27 GAAP EPS of $2.82 discounted back to and (b) an NPV of $17/share (discount rate 11.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.3% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on AC Immune SA is a Moderate Buy with an average price target of $18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
